Clinical Trial Update: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update investigating an aromatase inhibitor in adjuvant therapy combined with pertuzumab/trastuzumab for women with breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitor (unspecified) (aromatase inhibitor)
• pertuzumab/trastuzumab (pertuzumab and trastuzumab)

Snippet

Sponsor: Midwestern Regional Medical Center | Conditions: Breast Neoplasms | Phase 2 | Status: UNKNOWN